Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Wave Life Sciences Ltd

Healthcare US WVE

6.09USD
0.33(5.73%)

Last update at 2026-06-04T20:03:00Z

Day Range

5.766.24
LowHigh

52 Week Range

3.457.67
LowHigh

Fundamentals

  • Previous Close 5.76
  • Market Cap748.23M
  • Volume3413443
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-67.56000M
  • Revenue TTM112.91M
  • Revenue Per Share TTM1.00
  • Gross Profit TTM -73.64400M
  • Diluted EPS TTM-0.51

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -161.14200M -122.44900M -150.75100M -193.63800M -146.58400M
Minority interest - - - - -
Net income -161.82300M -122.24500M -149.91000M -179.49600M -146.65300M
Selling general administrative 50.51M 46.10M 42.51M 48.87M 39.51M
Selling and marketing expenses - - - - -
Gross profit 3.65M 40.96M 20.08M 15.98M 14.41M
Reconciled depreciation 10.11M 9.84M 9.98M 9.20M 5.58M
Ebit -172.83400M -127.01600M -153.37700M -208.31700M -162.89100M
Ebitda -162.72000M -127.04600M -153.96100M -213.22900M -157.31000M
Depreciation and amortization 10.11M -0.03000M -0.58400M -4.91200M 5.58M
Non operating income net other 1.58M 4.57M 2.64M - 12.92M
Operating income -162.72000M -127.01600M -153.37700M -208.31700M -159.52300M
Other operating expenses 166.37M 167.98M 173.45M 224.30M 173.94M
Interest expense -1.57800M 14.43M -0.01600M 0.00000M 0.02M
Tax provision 0.68M -0.20400M -0.84100M 0.00000M 0.07M
Interest income 1.57M - - 4.94M 3.39M
Net interest income 1.57M - -0.01600M 0.03M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.68M -0.20400M -0.84100M -14.14200M 0.07M
Total revenue 3.65M 40.96M 20.08M 15.98M 14.41M
Total operating expenses 166.37M 167.98M 173.45M 224.30M 173.94M
Cost of revenue - - - 175.43M 134.43M
Total other income expense net 1.58M 4.57M 2.63M 14.68M 12.92M
Discontinued operations - - - - -
Net income from continuing ops -161.82300M -122.24500M -149.91000M -193.63800M -146.65300M
Net income applicable to common shares -161.82300M -122.24500M -149.91000M -193.63800M -146.65300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 274.95M 146.39M 207.01M 279.24M 284.25M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.94M 2.11M 5.42M 5.11M 8.69M
Total liab 227.44M 191.48M 174.51M 196.46M 220.52M
Total stockholder equity 47.50M -45.09100M 32.50M 82.78M 63.73M
Deferred long term liab - - - - -
Other current liab 16.83M 17.55M 14.86M 11.97M 16.18M
Common stock 935.37M 802.83M 749.85M 694.09M 539.55M
Capital stock 935.37M 802.83M 749.85M 694.09M 539.55M
Retained earnings -1024.85000M -967.33700M -805.51400M -683.26900M -533.35900M
Other liab - 79.96M 77.48M 41.95M 65.19M
Good will - - - - -
Other assets - 3.72M 3.80M 3.77M 44.30M
Cash 200.35M 88.50M 150.56M 184.50M 147.16M
Cash and equivalents - - - - -
Total current liabilities 186.44M 71.52M 64.20M 121.04M 118.15M
Current deferred revenue 150.06M 31.56M 37.10M 91.56M 89.65M
Net debt -168.23300M -50.88300M -120.64800M -155.19200M -114.61400M
Short term debt 6.71M 5.50M 4.96M 3.71M 3.24M
Short long term debt - - - - -
Short long term debt total 32.12M 37.61M 29.92M 29.30M 32.55M
Other stockholder equity 129.24M 119.44M 87.98M 71.57M 57.28M
Property plant equipment - 17.28M 22.27M 29.20M 54.47M
Total current assets 235.37M 98.54M 162.56M 230.04M 185.48M
Long term investments - - - - -
Net tangible assets - -37.21700M 40.37M 90.65M 63.73M
Short term investments - - - - -
Net receivables 21.09M - 0.00000M 30.00M 20.00M
Long term debt - - - - -
Inventory 0.00000M - - 10.43M 9.63M
Accounts payable 12.84M 16.91M 7.28M 13.79M 9.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.12400M -0.02900M 0.18M 0.39M 0.27M
Additional paid in capital - - - - -
Common stock total equity - 802.83M 749.85M 694.09M 539.55M
Preferred stock total equity - - - - -
Retained earnings total equity - -967.33700M -805.51400M -683.26900M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.16M 3.72M 3.80M 3.77M 44.30M
Deferred long term asset charges - - - - -
Non current assets total 39.58M 47.85M 44.44M 49.20M 98.77M
Capital lease obligations 32.12M 37.61M 29.92M 29.30M 32.55M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.25500M -0.56000M -1.33800M -3.91800M -9.93800M
Change to liabilities 12.23M -4.15100M -0.34400M -19.48000M 11.32M
Total cashflows from investing activities -1.25500M -0.56000M -1.33800M -3.91800M -9.93800M
Net borrowings - - - - -0.01600M
Total cash from financing activities 67.19M 55.83M 154.54M 164.40M 65.09M
Change to operating activities - 2.04M 4.61M -13.82300M -4.13400M
Net income -161.82300M -122.24500M -149.91000M -193.63800M -146.65300M
Change in cash -62.05800M -33.93300M 37.34M -27.63600M 32.33M
Begin period cash flow 154.22M 188.15M 150.81M 178.44M 146.11M
End period cash flow 92.16M 154.22M 188.15M 150.81M 178.44M
Total cash from operating activities -127.78100M -88.99300M -115.98200M -188.23100M -22.86200M
Issuance of capital stock 52.33M 54.97M 153.63M 161.79M 60.00M
Depreciation 10.11M 9.84M 9.98M 9.20M 5.58M
Other cashflows from investing activities 0.11M - - - -
Dividends paid - - - - -
Change to inventory - 2.04M 4.61M -5.45400M -4.08200M
Change to account receivables 0.00000M 30.00M 20.00M 10.00M -59.00000M
Sale purchase of stock 66.08M 55.83M 94.66M 164.40M 65.11M
Other cashflows from financing activities 14.86M 0.86M 0.91M 2.61M -60.00000M
Change to netincome 17.21M 16.41M 14.30M 19.51M 15.64M
Capital expenditures 1.36M 0.56M 1.34M 3.92M 9.94M
Change receivables - 30.00M 20.00M - -59.00000M
Cash flows other operating -1.96700M -16.48700M -8.13800M - 149.27M
Exchange rate changes - - - - -
Cash and cash equivalents changes -61.84800M -33.72500M 37.22M - 32.29M
Change in working capital 6.72M 7.01M 9.65M -23.30300M 102.39M
Stock based compensation 17.19M 16.41M 14.30M 19.51M 15.60M
Other non cash items 0.01M 25.13M -32.03000M 1.61M 0.18M
Free cash flow -129.14200M -89.55300M -117.32000M -192.14900M -32.80000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
WVE
Wave Life Sciences Ltd		 0.33 5.73% 6.09 - - 6.26 17.90 4.77 -9.2025
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd

Marina One East Tower, Singapore, Singapore, 018936

Key Executives

Name Title Year Born
Dr. Paul B. Bolno M.B.A., M.D., MBA Pres, CEO & Director 1974
Dr. Chandra Vargeese Ph.D. Chief Technology Officer & Head of Platform Discovery Sciences 1961
Mr. Kyle B. Moran CFA CFO & Principal Accounting Officer 1971
Kate Rausch Head of Investor Relations NA
Ms. Linda Rockett J.D. Gen. Counsel NA
Dr. Christopher Francis Ph.D. Sr. VP of Corp. Devel. & Head of Emerging Areas 1978
Mr. Jonathan Rosin Chief HR Officer NA
Dr. Sridhar Vaddeboina Ph.D. Sr. VP of Chemistry, Manufacturing & Controls NA
Ms. Anne-Marie Li-Kwai-Cheung Chief Devel. Officer NA
Dr. Stephen L. Lake Sr. VP & Head of Clinical Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions